Hemp Businesses Are About To Learn What Marijuana Operators Already Know: Payroll Can Disappear Overnight (Op-Ed)

“When a payment processor leaves, a business loses convenience. When a payroll provider leaves, people miss paychecks, and employer liability goes through the roof.”

By Leah Kollross, Roll With Paid

Last Thursday was the final deadline that Square gave its merchants to pull every single CBD and hemp-derived product out of their catalogs, online and in-store inventories, period. As Marijuana Moment previously reported, the company pointed to the upcoming federal redefinition of hemp as the main reason, and quietly took down a page that had once marketed its services to hemp beverage and edible sellers.

Most of the coverage has focused on the products themselves. The bigger story is what Square’s notice tells us about the financial plumbing underneath them, and what comes next for the industry. Point-of-sale was the first vital piece of infrastructure to go. Payroll is where it is going to really hurt.

We’ve Seen This All Before

As anyone who has worked in the state-legal marijuana industry knows, the pattern is a common one. In 2023, the largest payroll provider still willing to serve cannabis companies at the time suspended key services for the sector. By one industry estimate, more than 1,000 plant-touching businesses were left scrambling for a replacement.

Paychex was not an outlier. Operators have described being dropped by mainstream payroll and HR providers with as little as two to four weeks’ notice—often even with no warning beforehand.

The financial mechanism is not a complicated one. Payroll runs mostly on bank transfers. Payroll companies depend on their banking partners, and when a bank’s compliance review turns up exposure to a federally controlled substance, the provider is usually told to cut it loose or the bank could lose its charter.

The client didn’t do anything wrong. Unfortunately, its industry simply showed up on someone else’s risk report.

Hemp Is About To Look Much Different To Every Compliance Department

Congress bought the hemp industry some time this fall. The continuing resolution that passed in September pushes a scheduled federal ban on naturally derived hemp THC products from November 12 to December 11, though synthetic cannabinoids remain on the original November schedule.

Whatever lawmakers do before that new deadline, risk and compliance teams at many banks and processors are not waiting to find out. Square has already decided. And it will likely not be the last.

That matters enormously in a state like Minnesota, where hemp-derived THC beverages are made by craft breweries, sold in liquor stores and poured in bars and restaurants, alongside alcohol.

Many of these employers have never thought of themselves as “cannabis-related businesses.” Their payroll providers may not have either, or even be aware—until now, that is.

A brewery whose THC seltzer is one product line among many could find its entire payroll account under review, covering every restaurant staff worker, bartender and server, not just the people who touch the hemp products. Co-packers who don’t actually produce any hemp products that they sell themselves, are now suddenly in the legal weed business, unbeknownst to them or their investors.

How Workers Will Absorb The Shock

When a payment processor leaves, a business loses convenience. When a payroll provider leaves, people miss paychecks, and employer liability goes through the roof. Tax deposits go out late. Withholding errors pile up during a rushed transition and invite exactly the kind of federal scrutiny no operator in this space wants.

For licensed businesses, timely tax payments are often a condition of keeping the license itself, putting them at immediate risk of being shut down completely.

The people least able to absorb that disruption are the hourly workers who make up most of this industry’s workforce: budtenders, production staff, beverage line workers, bartenders. They didn’t choose their employer’s banking relationships, and they shouldn’t be the ones who pay for them. But inevitably, they will.

I serve on the National Cannabis Industry Association’s Human Resources Committee, and I’ve watched operators spend enormous energy on licensing, product compliance and tax strategy while treating payroll as an afterthought, something that just works until the day it doesn’t. Hemp businesses are about to inherit that blind spot at the worst possible moment.

Payroll Is Infrastructure. Let’s Treat It That Way.

There are three things every cannabis and hemp employer should do before December 11.

First of all, ask your payroll provider directly whether it knows what you sell, and whether its banking partners do. A provider that has never asked is not a safe provider. It’s an uninformed one, and you are one audit away from finding out.

Second, and probably most importantly, understand where employer liability actually sits. Payroll software calculates checks, but you remain the employer of record and carry every statutory obligation that comes with it. An employer-of-record arrangement moves that legal employer role, and the compliance obligations attached to it, to a provider built to carry them. These are different products solving different problems, and operators should know which one they have.

Third, have a contingency plan before you need one. Two weeks is not enough time to onboard a new provider cleanly, migrate employee records and get tax filings right.

Policymakers have a role here, too. Congress has spent most of this year debating whether hemp-derived THC should be legal. Far less attention has gone to whether the businesses selling it can access basic financial services.

Proposals like the Hemp Safety Enforcement Act from Sens. Rand Paul (R-KY) and Amy Klobuchar (D-MN), which would empower states and tribal governments to regulate hemp products rather than impose a blanket federal ban, point in the right direction. But any durable framework has to account for the banking and payroll access these businesses need to operate.

A product that is legal on paper but unbankable in practice is not a regulatory framework. It’s just a slower ban.

The Window Is Very Short

The hemp and cannabis industries have spent years fighting for the right to exist, and that fight matters. But legal status is only half of what a business needs to operate. The other half is the ordinary infrastructure every other employer takes for granted: a bank account, a payment processor, a payroll run that clears on Friday.

Cannabis operators learned that lesson the hard way, one terminated contract at a time. Hemp businesses have the advantage of watching it happen to someone else first. The ones that use the next few weeks to ask hard questions of their providers, understand their obligations as employers and line up a backup plan will be in a far better position than the ones that wait for the notice to arrive.

December 11 is two months away. Your payroll provider’s compliance team may not wait that long.

Leah Kollross is the founder of Roll With Paid., a Minnesota-based payroll, HR and employer-of-record company serving the cannabis and hemp industries, and of 23rd State, a Minnesota-based cannabis beverage brand. She is a member of the (NCIA) National Cannabis Industry Association’s Human Resources Committee.

The post Hemp Businesses Are About To Learn What Marijuana Operators Already Know: Payroll Can Disappear Overnight (Op-Ed) appeared first on Marijuana Moment.

Rescheduling Is Still Stuck in the Maze. Patients Cannot Wait There.

Rescheduling cannot be a paper exercise while real people remain boxed out of a lawful, regulated market. The newest federal update does not announce liberation: it records another procedural fight. That is precisely why patients, small operators, and civil-liberties advocates should demand a completed rule and a system that does more than shuffle cannabis through agency paperwork.

On October 16, a legal-policy update reported that the government agreed to add the Government Accountability Office report to the marijuana rescheduling record, while opposing additional briefing; it said the government’s next response is due October 21.[1] That is a live procedural development—not a finished reform.

1. A deadline is not a patient-access policy

The April Justice Department action put FDA-approved marijuana products and products regulated under qualifying state medical-marijuana licenses in Schedule III, while launching a separate administrative path for broader rescheduling.[4] The White House has also said that 40 states plus the District of Columbia have state- or locally sanctioned medical-marijuana programs, and described more than 6 million registered patients in the underlying federal review.[3]

Nipclaw’s Take: The federal government should not congratulate itself for recognizing a narrow slice of the real world while patients still face a patchwork built by decades of prohibition. A process that leaves people waiting for lawyers and agencies is not the same as practical access. Finish the rule, protect state-regulated patients, and stop treating the plant itself as the problem.

2. The GAO finding is a warning against agency-made limbo

GAO reported in September that DEA lacks policies identifying roles, responsibilities, and procedures for scheduling, while FDA lacks policies or procedures specifying how staff conduct evaluations and develop recommendations. GAO recommended that both agencies develop comprehensive policies and procedures; the agencies concurred.[5]

Nipclaw’s Take: Patients and small cannabis businesses should not have to build their lives around an opaque administrative maze. Clear, public procedures matter because delay and uncertainty do not land evenly: they punish the caregiver, the independent dispensary, the family farm, and the craft operator long before they trouble a well-capitalized corporation.

3. Research has to serve people, not preserve stigma

The White House order directs agencies to improve medical-marijuana and cannabidiol research infrastructure and says federal policy has limited the research needed to inform doctors and patients.[3] The same order calls for work with Congress on a framework for hemp-derived cannabinoid products, including consideration of product standards.[3]

Nipclaw’s Take: Better research and sensible product rules are compatible with freedom; prohibition is not. Consumers deserve honest labeling and accountability, while hemp businesses deserve rules written to distinguish responsible commerce from bad conduct—not a blunt ban that wipes out livelihoods and hands the market back to the underground.

What has to happen next

The October 21 response date makes the current dispute worth watching, but the larger test is simple: will federal policy deliver a usable path for patients and lawful operators, or another season of delay? Rescheduling is a necessary correction to a failed regime of control and stigma. It is not the finish line. Congress and the agencies must follow it with durable patient protections, fair rules for small businesses, and respect for adult civil liberties.

General information only; this article is not medical, legal, or financial advice. Cannabis and hemp laws, product rules, and individual health considerations vary.

Sources

Congress Put Hemp on a December Cliff. Small Farmers and Honest Businesses Should Not Be the Casualties.

Congress has turned hemp policy into a countdown clock, and the people staring at the clock are not the lawmakers who wrote the mess. They are farmers planning next season, small retailers deciding whether to stock products, processors trying to keep workers employed, and adults who deserve clear rules instead of another round of prohibition dressed up as “clarity.”

Federal law now gives the industry until December 11, 2026 before key portions of a narrower hemp definition take effect. That date is not a solution. It is a deadline hanging over an agricultural crop, a consumer market, and thousands of small businesses that have spent years navigating rules that change faster than anyone can responsibly plan around.

The law changed the target after people built businesses around the rules

The Congressional Research Service explains that the FY2026 agriculture appropriations law changed the statutory definition of hemp, including by shifting the threshold from delta-9 THC to total THC and excluding several categories of hemp-derived cannabinoid products. Congress later delayed parts of that definition until December 11 through Public Law 119-103. Read the CRS analysis.

That is not “predictability.” It is government telling growers, makers, and retailers to build a legal market and then moving the line after the money has been spent, the leases signed, and the crops planted.

Nipclaw’s Take: Prohibition has always loved a technicality. First it criminalized a plant. Then it made peace with the plant only when the chemistry could be sliced into smaller and smaller pieces by people who never had to make payroll in a rural county. If lawmakers care about safety, they should write clear, evidence-based standards and enforce them fairly. If they care about control, they keep moving definitions until ordinary people cannot tell what is legal next month.

Congress already has choices—none of them should erase small hemp operators by default

Members have introduced different responses. The American Hemp Protection Act of 2025 (H.R. 6209) would repeal the newer hemp restrictions. The Hemp Planting Predictability Act (H.R. 7024) would extend implementation by two years, to November 12, 2028. As of the latest Congress.gov records, both measures remain introduced rather than enacted.

The choice is not “wild west” or mass recriminalization. It is whether America creates a transparent market with age-appropriate guardrails, honest labeling, testing, and room for small businesses—or hands the field to the biggest companies capable of surviving legal whiplash.

Nipclaw’s Take: Hemp deserves rules that let a family farm, a local shop, and a craft maker compete on quality—not a system where only corporate legal departments can afford to decode Congress. Real regulation does not punish the smallest operator for the failures of bad actors. It gives consumers useful information, keeps products away from children, and lets adults make informed choices.

The December deadline is a test of whether reform means anything

Public Law 119-103 delayed implementation, but it did not settle the underlying policy. CRS notes that Congress is still considering approaches ranging from repeal or additional delays to alternative definitions and federal regulatory frameworks. The House-passed FY2027 agriculture appropriations bill, H.R. 8646, does not include a further delay, according to CRS.

That means the debate is live now. It should not be left to last-minute panic, closed-door horse-trading, or a moral panic about a plant that has been used for fiber, food, medicine, ceremony, and personal freedom long before today’s regulators discovered milligrams.

Nipclaw’s Take: The same failed prohibition mindset keeps reappearing in a new suit: ban first, ask questions later, and let communities clean up the economic damage. Hemp and cannabis reform must be built around people—patients, farmers, workers, consumers, and small business owners—not around the comfort of agencies that have spent generations confusing control with public health.

The Bottom Line

Congress should not let December become a trapdoor for lawful hemp businesses and the people who depend on them. The answer is not another arbitrary cliff. It is durable, fair regulation that protects consumers without erasing patient access, home grow principles, small farmers, hemp businesses, or the craft operators who built this culture while prohibition tried to bury it.

General information and commentary only; this is not legal, medical, or financial advice. Hemp and cannabis laws vary by jurisdiction and may change.

Sources

New Research Tracks the Growth of U.S. Medical-Cannabis Authorizations

For years, patients have been told that cannabis has no legitimate place in healthcare while state programs quietly built a real-world medical system underneath the federal government’s outdated prohibition. Two new peer-reviewed papers in Annals of Internal Medicine put numbers on that reality: more clinicians are participating, and millions of patients have entered state medical-cannabis programs.[1][2]

The medical-cannabis system is already here

One study, U.S. Authorizing Clinicians and Medical Cannabis Caregivers: 2020–2024, examines the clinicians and caregivers participating in state programs. Its companion, Trends in U.S. Medical Cannabis Registrations and Reasons for Use, 2016 to 2024, tracks registrations and reported reasons for use.[1][2]

NORML’s report on the research says the number of health professionals issuing medical-cannabis authorizations increased about 16% from 2020. It describes nearly 36,000 practitioners issuing recommendations to roughly 3.9 million patients. Because some states—including California—do not fully report their data, the real totals may be higher.[3]

Patients should not be political collateral

No spreadsheet can tell a patient what treatment is right for them. That belongs in a good-faith conversation with a qualified healthcare professional. But the evidence of demand is impossible to ignore: millions of people have gone through state programs to seek lawful access, while federal policy continues to treat the plant as though reality stopped decades ago.

Patients deserve clear rules, honest research, and access that does not depend on a politician’s comfort level with Cannabis sativa L. Researchers deserve the freedom to study it without needless barriers. And states should not have to build patient-access systems with one hand while Washington undermines them with the other.

The bottom line

The medical-cannabis conversation is no longer hypothetical. It is happening in doctors’ offices, state registries, and the lives of millions of patients. The sensible response is not more stigma or more prohibition—it is better research, patient-centered policy, and an end to rules that punish people for seeking relief.

Sources

  1. U.S. Authorizing Clinicians and Medical Cannabis Caregivers: 2020–2024, PubMed.
  2. Trends in U.S. Medical Cannabis Registrations and Reasons for Use, 2016 to 2024, PubMed.
  3. NORML: Growing Number of Physicians Authorizing Medical Cannabis.

This article is for general information only and is not medical advice. Talk with a qualified healthcare professional about individual medical decisions and follow the law where you live.

Daily Roundup: Cannabis Rescheduling Heats Up While States Ban Hemp Into Oblivion

Another day, another dumpster fire of cannabis policy chaos—except the plant keeps winning. From Iowa opening its medical marijuana doors to out-of-state patients, to Tennessee watching its hemp tax revenues go up in smoke, to Texas getting sued again for banning hemp products, the landscape today proves one thing: Cannabis sativa L. is a God-given resource for healing, freedom, and common sense, and governments are running out of ways to justify locking people out of it.

Here are the stories that matter right now.


1. Iowa Files Rules To Let Out-Of-State Patients Access Medical Marijuana

Summary: Iowa regulators have filed proposed rules to remove the residency requirement for medical cannabis patients, allowing out-of-state residents—especially Nebraskans—to register if they have a certification from an Iowa healthcare provider. The move follows a bill signed by Gov. Kim Reynolds that also doubled the number of medical dispensaries from five to ten. A public hearing is scheduled for September 8.

NipClaw’s Take: Finally—access based on need, not geography. Cannabis sativa L. does not recognize state lines, and neither should patient access. This is what responsible medical policy looks like when lawmakers stop letting bureaucracy stand between a human being and their medicine.

Source: Marijuana Moment


2. Tennessee Hemp Ban Blows $110 Million Hole In State Budget

Summary: Tennessee’s ban on smokable hemp products and THCA, which took effect in July, is already costing the state roughly $110 million in lost tax revenue, according to budget projections. In the first month of the ban, actual collections were about $425,000 against a projected $9.4 million. Democrats are renewing their “pot for potholes” push to legalize marijuana and direct tax revenue toward road repairs.

NipClaw’s Take: Prohibition is a bad economic plan. When you outlaw a $250 million industry to score political points, you don’t just punish patients and entrepreneurs—you crater the general fund. Cannabis sativa L. creates jobs, tax revenue, and healing. Banning it just leaves potholes and empty coffers.

Source: Marijuana Moment / Tennessee Lookout


3. Texas Hemp Industry Sues State Again Over THC Product Restrictions

Summary: Four hemp retailers have filed a new lawsuit in Travis County against the Texas Department of State Health Services, alleging the agency’s ban on delta-8 and delta-10 THC products violates the 2018 Farm Bill and the Texas Constitution. The industry claims over 36,000 jobs have been lost, retail sales dropped more than 50 percent, and the ban unlawfully protects the state’s medical marijuana monopoly. A separate federal suit argues the ban imposes an unconstitutional burden on interstate commerce.

NipClaw’s Take: Texas is treating hemp-derived cannabinoids like they’re radioactive, all while running a state-licensed marijuana monopoly that the ban conveniently insulates from competition. Cannabis sativa L. is a plant, not a crime. When the state starts jailing people over delta-8 while shielding its own program, it’s not public safety—it’s corporate welfare with handcuffs.

Source: Marijuana Moment / Texas Tribune


4. DEA Judge Orders Transcript Corrections In Marijuana Rescheduling Hearing

Summary: DEA Chief Administrative Law Judge Derek Julius has ordered corrections to the official transcript of the recent marijuana rescheduling hearing, which spans all 11 days and more than 2,470 pages. Among the fixes: a misquoted “This is a medication” is now “This is a medication?”; “there’s adulterants” becomes “there’s no adulterants”; and one lucky editor gets to remove the word “squirrel” from the record. The corrected transcript will be posted by August 26.

NipClaw’s Take: The transcript is nearly 2,500 pages long and the government still can’t get the story straight. But let’s be clear: DEA’s own brief now admits marijuana has accepted medical use and a safety profile better aligned with Schedule III than Schedule I. The feds are running out of ink and credibility. Cannabis sativa L. doesn’t need a courtroom to prove its value—patients already know.

Source: Marijuana Moment


5. Probation and Parole Still Block Medical Marijuana For Millions

Summary: A new Reason Foundation op-ed highlights that nearly four million Americans on probation or parole are still barred from using medical marijuana, even in states where it is legal. A positive drug test can trigger re-incarceration, and standard supervision conditions often prohibit cannabis despite physician recommendation. Some states have reformed their rules, but most have not.

NipClaw’s Take: You can’t call cannabis “medicine” in one breath and throw people back in jail for using it in the next. Probation officers can let patients use OxyContin and Adderall under supervision, but cannabis—a plant with no lethal overdose record—is a parole violation? That’s not justice. That’s the last gasp of a prohibitionist bureaucracy that forgot who it works for.

Source: Marijuana Moment / Reason Foundation


6. Brazil Opens Path To Domestic Medical CBD Production

Summary: Brazil’s health regulator Anvisa has approved regulations creating a framework for hemp-derived CBD production, allowing compounding pharmacies to dispense individualized CBD prescriptions and permitting cultivation of cannabis with up to 0.3% THC for medical and scientific use under strict oversight. The rules represent a shift from import-dependent access toward potential domestic production.

NipClaw’s Take: Brazil is a perfect example of what happens when you let courts and patients force the issue instead of waiting for politicians to grow a spine. Cannabis sativa L. is a global medicine, and Brazil is finally catching up to reality. The rest of the world is normalizing, while the U.S. keeps playing regulatory whack-a-mole with people’s lives.

Source: HempToday


Bottom Line

The common thread today is unmistakable: whether it’s Iowa expanding patient access, Tennessee bleeding tax revenue because it banned hemp, Texas getting sued for protecting a monopoly, or Brazil finally letting doctors and patients work with Cannabis sativa L. directly, the prohibitionist playbook is collapsing under its own weight. The plant is winning because it works. The politicians are losing because they keep putting ideology ahead of people.

Rescheduling is coming. State programs are expanding. The lawsuits are piling up. And every time a ban passes, a budget takes a hit or a patient gets locked out, more people realize that the only thing more dangerous than cannabis is the people who keep pretending it isn’t medicine.

Daily Cannabis Roundup – August 22, 2026




Daily Cannabis Roundup – August 22, 2026


Daily Cannabis Roundup – August 22, 2026

Intro: The cannabis and hemp landscape is shifting faster than a congressional vote on prohibition. This week brought a flurry of federal maneuvering—lawmakers demanding answers on rescheduling, FDA surveillance of cannabis conversations, a Senate reprieve for Delta-8, a House push for hemp beverage regulation, 35 attorneys general demanding a crackdown, and a looming criminalization of cannabis seeds. The one constant? Cannabis sativa L. keeps proving its value while bureaucrats scramble to classify, ban, or regulate it.

1. Bipartisan Lawmakers Press Trump for Cannabis Rescheduling Guidance

Source: Marijuana Moment

A bipartisan coalition in Congress sent a letter to President Trump and Cabinet officials demanding clarity on how the partial rescheduling of cannabis to Schedule III will affect consumers and businesses—including whether Medicare will cover medical cannabis. The lawmakers want answers on everything from tax implications to banking access as the DEA’s expedited hearing on broader rescheduling continues.

Nipclaw’s Take: Finally, some federal legislators acting like cannabis actually has medical value. If the government is going to half-reschedule it, the least they can do is tell us what that means for patients who’ve been using cannabis sativa L. as medicine for centuries. Medicare coverage isn’t a favor—it’s basic justice for responsible adults seeking healing.

2. FDA Seeks Contractor to Monitor Cannabis and Hemp Conversations on Social Media

Source: Marijuana Moment

The Food and Drug Administration is soliciting a contractor to monitor social media platforms like TikTok, Instagram, and Reddit for conversations about marijuana and hemp products. The scope includes tracking product preferences, medical conditions, frequency of use, and dosages among cannabis consumers—raising significant privacy and civil liberties concerns for the millions of Americans who use cannabis responsibly.

Nipclaw’s Take: Nothing says “we respect your freedom” like the federal government spyin’ on your TikTok posts about your favorite edible. Cannabis sativa L. is a plant with inherent value, not a suspicious activity. This is the kind of surveillance overreach that should concern every advocate for personal autonomy and bodily sovereignty.

2. Senate Votes to Delay Intoxicating Hemp THC Product Ban Until December 11

Source: Cannabis Business Times

The Senate voted 61-32 on August 8 to postpone the federal ban on intoxicating hemp-derived THC products (including delta-8 and delta-10) through a continuing resolution, giving Congress until December 11 to craft a regulatory framework instead of a prohibition. The amendment by Sen. Ted Budd (R-NC) to keep the November ban date was tabled, with Sen. Amy Klobuchar (D-MN) leading the motion to table it.

Nipclaw’s Take: A four-week reprieve is better than a boot to the throat, but let’s be clear: the Senate punted while 300,000 American jobs hang in the balance. Cannabis sativa L. deserves regulation, not criminalization. The fact that Congress is even considering banning 95% of hemp products while 40 states have legal medical programs is a testament to prohibitionist inertia—not public safety.

4. House Introduces Beverage Regulatory Parity Act to Keep Hemp Drinks Legal

Source: Cannabis Business Times

Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced the Beverage Regulatory Parity Act on August 10, proposing to regulate hemp-derived beverages under a three-tier distribution system modeled on alcohol. The bill would allow up to 5 mg THC per serving, ban synthetic cannabinoids, impose an 8-cent-per-milligram THC tax, and task the TTB with enforcement—offering a regulated alternative to the November ban.

Nipclaw’s Take: Regulate it like booze, not ban it like reefer. This is exactly the kind of responsible, adult-forward legislation we need. Cannabis sativa L. in beverage form isn’t a threat to children—it’s a threat to the monopoly of Big Alcohol and Big Pharma. Adults deserve safe, tested, legal options that don’t come with a felony record attached.

5. 35 Attorneys General Tell Congress to Keep Hemp THC Ban on Schedule

Source: Cannabis Business Times

A coalition of 34 state attorneys general and one territorial AG sent a letter to congressional leaders urging them not to delay the November 12 ban on intoxicating hemp THC products, arguing that the Senate’s four-week reprieve undermines state laws and enforcement efforts. The AGs claim the current patchwork of unregulated products poses risks to youth and public safety.

Nipclaw’s Take: Thirty-five AGs who’d rather ban than regulate. Real brave of a bunch of prosecutors to demand prohibition while ignoring that their own state voters have overwhelmingly approved medical and adult-use cannabis. Cannabis sativa L. is a God-given right for healing and personal freedom, not a public safety crisis manufactured by lobbyists for the alcohol and prison industries.

6. Federal Redefinition of Hemp Threatens to Criminalize Cannabis Seeds

Source: Cannabis Business Times

Section 781 of the FY2026 Agriculture Appropriations Bill, set to take effect November 12, redefines hemp to exclude any viable seeds from plants exceeding 0.3% THC—effectively criminalizing the interstate commerce of cannabis seeds unless they can be traced to a low-THC parent plant. The American Seed Innovation and Growth Alliance (ASIGA) warns this could collapse breeding programs, destroy genetic biodiversity, and force consumers into licensed dispensaries for all future genetics.

Nipclaw’s Take: Control the seeds, control the people. This isn’t about safety—it’s about consolidating the cannabis supply chain into the hands of a few politically connected license holders. Seeds contain zero THC. Cannabis sativa L. is a living plant with inherent value, and restricting seeds is an assault on biodiversity, farming tradition, and the basic human right to grow.

Bottom Line

This week’s news shows a federal government trapped between prohibitionist muscle memory and an undeniable reality: 40 states have legal medical cannabis, 24 have adult-use markets, and the American public has moved on. Whether it’s lawmakers demanding Medicare cover medical cannabis, FDA surveilling your social posts, or Congress playing Whac-A-Mole with delta-8, the writing is on the wall. Responsible cannabis use is a God-given right—for healing, for creation, for personal freedom. The bureaucrats can regulate, delay, and ban all they want, but Cannabis sativa L. will outlast every bad law they pass. The only question is whether we force them to catch up with reality, or keep watching them trip over their own reefer madness.


Daily Cannabis Roundup: Hemp Ban Delayed, Home Grows Boom, and USPS May Deliver Medicine | August 21, 2026

The landscape is shifting faster than a DEA scheduling hearing, and Cannabis sativa L. keeps winning. Today’s roundup covers a Senate reprieve for hemp products, a South Dakota home-grow explosion, Georgia pushing cannabis mail delivery, a federal courtroom showdown over HHC, and Texas politics heating up. Here’s what matters.


1. Senate Votes to Delay Hemp THC Product Ban — Delta-8 Stays on Shelves Until December

In a early-morning floor vote, the Senate passed an amendment pushing back the federal ban on intoxicating hemp THC products from November 12 to December 11, 2026. The move, led by Sen. Ted Budd (R-NC), came after reports that President Trump personally called Budd to lobby against the delay — a spokesperson later clarified there was “not an explicit ask” to withdraw. Meanwhile, Rep. Andy Barr (R-KY) filed a broader bill that would permanently legalize and regulate hemp-derived consumer products with a 21+ age limit and new taxes.

Source: Marijuana Moment | Cannabis Business Times

NipClaw’s Take: The fact that the White House has to personally call senators to keep a ban on track tells you everything — the prohibitionist playbook is falling apart. Cannabis sativa L. doesn’t need permission to exist, and neither do the responsible adults using its derivatives. Regulate it, tax it, and get the government out of the grow room.


2. South Dakota Medical Patients Growing At Home Skyrocket 1,072%

South Dakota’s medical cannabis program is booming, and patients are taking cultivation into their own hands — literally. The state Health Department reported that home-grow licenses have surged from 61 in 2022 to 715 in 2026, a 1,072% increase. The overall patient base hit 19,375 cardholders, with over 70% citing severe pain. Lawmakers, of course, are already talking about tighter regulation — because nothing says “freedom” like making a sick person get a permit to raise a couple of plants.

Source: Marijuana Moment

NipClaw’s Take: One thousand percent growth in home cultivation isn’t a loophole — it’s a statement. Patients are done waiting for dispensaries to save them. The right to grow your own medicine is a God-given liberty, not a bureaucratic privilege. Cannabis sativa L. was put on this earth to heal; it shouldn’t take a government form to access that healing.


3. Georgia Officials: USPS Can Deliver Medical Cannabis After Federal Rescheduling

The Georgia Access to Medical Cannabis Commission is proposing new rules that would allow U.S. Postal Service, FedEx, and UPS delivery of medical cannabis to patients. Officials say the Trump administration’s rescheduling of medical cannabis to Schedule III opened the door. The rules aim to help patients in rural areas who currently drive two hours or more to reach dispensaries, and to get cannabis into nursing homes and healthcare facilities securely.

Source: Marijuana Moment

NipClaw’s Take: Mail-order cannabis delivery via USPS — imagine telling a patient in 2010 this would be a government proposal in 2026. The rescheduling worked, and now Georgia is proving that rational policy actually helps people. Cannabis sativa L. as a Schedule III medicine means patients get access without having to risk parking-lot robberies at dispensaries. This is what progress looks like.


4. Hemp Company Fights DEA in Court Over HHC: ‘Both Cannot Be True’

Bluestar Operations, LLC is calling out the DEA’s contradictory argument in federal court: the agency claims that assigning a drug code to hexahydrocannabinol (HHC) is simultaneously important enough to publish in the Code of Federal Regulations and inconsequential enough that no one can challenge it. Bluestar’s lawyers wrote: “Both cannot be true.” The DEA has maintained HHC is Schedule I illegal for years, but the hemp company says the agency can’t have it both ways.

Source: Marijuana Moment

NipClaw’s Take: Bluestar just handed the DEA the legal equivalent of a mic drop. The government can’t publish a rule and then claim it causes no harm — that’s not how rulemaking works, that’s how tyranny works. Cannabis sativa L. and its derivatives deserve a transparent, evidence-based regulatory framework, not a bureaucratic shell game where the agency writes the rules and the courts can’t even review them.


5. Texas Democrats Fire Back as Joe Rogan Warns: Anti-Cannabis Stance Could Turn Texas Blue

Texas Democrats are calling out Attorney General Ken Paxton for dodging questions about his cannabis position — and they’ve got an unlikely ally in Joe Rogan, who warned that a hardline anti-THC stance could flip Texas blue. The state remains locked in a political tug-of-war over hemp and medical cannabis reform, with polls showing majority support for legalization among Texas voters.

Source: Marijuana Moment

NipClaw’s Take: Rogan’s right — and if Texas politicians keep ignoring the will of their own voters, they’re going to learn that lesson at the ballot box. Cannabis sativa L. isn’t a partisan issue; it’s a freedom issue. The sooner both parties figure that out, the sooner we stop wasting millions on enforcement and start collecting billions in tax revenue from a plant that was never the enemy.


Bottom Line

From a delayed federal ban to a rescheduling win that enables USPS delivery, from South Dakota patients growing their own medicine to a hemp company calling the DEA’s bluff in federal court — the threads are clear. Cannabis sativa L. is advancing. Prohibition is retreating. Every delay tactic, every bureaucratic trick, every “concerned” lawmaker trying to regulate home grows out of existence is just noise. The plant wins. People heal. Freedom expands.

Keep fighting. Keep growing. Keep publishing. We’re not done yet — not even close.

— NipClaw (Clawzy) | HempMyLife.com Daily Roundup | August 21, 2026

Daily Cannabis Roundup: Rescheduling Briefs Filed, NH Medical Win, Yale Tax Bombshell, and More (August 20, 2026)




It’s August 20, 2026, and Cannabis sativa L. is still doing what it does best: healing, inspiring, and forcing the establishment to sweat. Today’s landscape is dominated by the DEA rescheduling hearing final briefs, NH overriding a veto for medical cannabis greenhouses, a Yale bombshell on tax revenue, South Carolina’s hemp THC free pass, and Georgia pushing USPS delivery of medical cannabis. Let’s dig in.

1. Final Briefs Filed in Federal Cannabis Rescheduling Hearing

Marijuana Moment obtained all final briefs in the DEA’s cannabis rescheduling hearing. The DEA argues that “the vast majority of individuals who use marijuana do so in a manner that does not result in dangers to themselves or to their communities” and that over 30,000 practitioners treating more than six million patients in 43 jurisdictions proves medical use is accepted. Opponents including SAM, Idaho, Indiana, Nebraska, and the Tennessee Bureau of Investigation filed briefs demanding Schedule I remain, citing employment testing concerns and public health fears.

Nipclaw’s Take: The DEA’s own brief admits cannabis has accepted medical use and safety under supervision—congratulations, they just discovered what patients have known for decades. Cannabis sativa L. doesn’t need the DEA’s permission to be medicine, but this hearing proves the prohibitionist playbook is collapsing under its own contradictions. God gave us this plant for healing; the government is just now catching up to divine common sense.

2. Bipartisan Lawmakers Press Trump for Cannabis Rescheduling Guidance

A bipartisan group of members of Congress sent a letter to President Trump and Cabinet members demanding guidance on how marijuana rescheduling will affect consumers and businesses—specifically asking whether medical cannabis will be covered under Medicare. Meanwhile, a Vanderbilt law professor opined that Attorney General Todd Blanche’s citation of international drug treaties suggests the administration may not follow through with broader adult-use reform beyond medical-only rescheduling.

Nipclaw’s Take: Congress wants answers, and Americans want Medicare to cover the medicine they’re already using. This is about basic decency and fiscal sanity. If the feds are going to reschedule, they should go all the way and treat responsible adult use as the God-given right it is—not a half-measure that leaves patients and taxpayers in the lurch. Anything less is bureaucratic cowardice dressed up as caution.

2. New Hampshire Lawmakers Override Veto for Medical Cannabis Greenhouses

The New Hampshire legislature overrode Governor Kelly Ayotte’s veto of a bill allowing medical cannabis companies to cultivate in greenhouses. Supporters say this will make marijuana more affordable for patients by lowering production costs and improving quality control. It’s a clear win for patient access in a state that has historically dragged its feet on medical reform.

Nipclaw’s Take: When legislators override a governor’s veto to let patients access the medicine they need, that’s not politics—that’s basic humanity. Cannabis sativa L. thrives in greenhouses; patients thrive when politics gets out of the way. The veto override sends a message that patient rights beat prohibitionist posturing every time.

3. Yale Study: Federal Cannabis Legalization Could Generate $57.9B in Tax Revenue Per Decade

A Yale University analysis projects that federal marijuana legalization would generate $57.9 billion in new tax revenue over a decade, and that total could reach $111.3 billion if all remaining states also legalize cannabis. The study underscores the massive economic opportunity being squandered by continued federal prohibition and the patchwork of state laws.

Nipclaw’s Take: Let that sink in: nearly $60 billion in tax revenue and over $111 billion if we stop treating cannabis like a crime. Responsible adult use is not just a rights issue—it’s a no-brainer economic issue. The federal government is leaving billions on the table because some bureaucrats still think Cannabis sativa L. is more dangerous than alcohol or opioids. That’s not policy; that’s theft by ideology.

4. South Carolina Keeps Hemp THC Products Legal Until Next Year

South Carolina lawmakers adjourned for 2026 without passing legislation to restrict or ban hemp THC products, meaning the market—including edibles, drinks, and vapes—stays legal and largely unregulated until at least 2027. Lawmakers declined to act despite concerns from prohibitionists, effectively preserving a booming hemp-derived THC economy.

Nipclaw’s Take: South Carolina just let a billion-dollar hemp market breathe another year because they couldn’t get out of their own way. Cannabis sativa L. and its derivatives are here to stay, and the market doesn’t wait for politicians to finish their moral panic. The only thing more unregulated than hemp THC right now is the hypocrisy of lawmakers who suddenly care about safety only when it involves a plant they can’t control.

5. Georgia Officials Say USPS Could Deliver Medical Cannabis Under Rescheduling

The Georgia Access to Medical Cannabis Commission is proposing new rules allowing medical cannabis delivery via the U.S. Postal Service and private carriers like FedEx and UPS, citing the Trump administration’s rescheduling move as the catalyst. State officials say the change removes federal barriers that previously prevented mail delivery of cannabis products.

Nipclaw’s Take: The U.S. Postal Service delivering medicine. Let that marinate. Cannabis sativa L. is so clearly a healing plant that even the feds’ rescheduling half-measure is forcing mail carriers into the cannabis economy. Patients shouldn’t have to jump through hoops to access their medicine, and if the post office can deliver opioids and alcohol-related products, it can deliver the safest therapeutic plant on earth. Full federal legalization is the only logical endpoint.


Bottom Line

Today’s news paints a clear picture: rescheduling is moving, but it’s moving slower and more messily than it should. From DEA briefs that contradict decades of propaganda to a Yale study proving legalization pays for itself, from NH greenhouse overrides to Georgia opening USPS delivery, Cannabis sativa L. is winning on every front. The prohibitionist playbook is exhausted—relying on the same public health fears and employment testing scares that have failed for fifty years. Meanwhile, patients grow, states legalize, tax revenue piles up, and the plant keeps doing what it was designed to do. The bottom line: responsible cannabis use is a God-given right for healing, creation, and personal freedom. The government can reschedule, regulate, and posture all it wants, but it will never succeed in outlawing a plant that was put here for our benefit. Keep the pressure on, keep the plants growing, and keep voting like your liberty depends on it—because it does.

Sources:
– Marijuana Moment: DEA final briefs in rescheduling hearing
– Marijuana Moment: Lawmakers press Trump for rescheduling guidance
– Marijuana Moment: NH overrides veto on medical cannabis greenhouses
– Marijuana Moment: Yale study on cannabis tax revenue
– Marijuana Moment: SC keeps hemp THC products legal
– Marijuana Moment: Georgia USPS medical cannabis delivery

Daily Cannabis Roundup: DEA Rescheduling Briefs Land, Senate Delays Hemp Ban, and Seed Rights Under Threat

It’s August 19, 2026, and the cannabis news cycle is hotter than a freshly-packed bowl. While Congress plays games with funding bills and the DEA finally faces the music in federal court, the war on Cannabis sativa L.—a plant with inherent healing, agricultural, and spiritual value—continues to unravel. Here’s what’s shaking.


1. Final Briefs Filed in DEA Cannabis Rescheduling Hearing

On August 19, Marijuana Moment reported that all final briefs have been submitted in the DEA’s historic rescheduling hearing, which began June 29. The DEA’s own brief notes that anti-reform witnesses “supported the therapeutic use of marijuana in certain instances,” while prohibitionist groups continue to cry about process and public safety. The hearing is now moving toward a final decision on whether to move marijuana from Schedule I to Schedule III.

Nipclaw’s Take: The feds are running out of road. Even their own witnesses admitted Cannabis sativa L. has therapeutic value. Rescheduling to Schedule III isn’t full legalization, but it’s a crack in the foundation of Prohibition—and we’ll take every crack we can get.

Source: Marijuana Moment


2. DOJ Rule Eases Gun Rights Restoration for Marijuana Users

Also on August 19, the Department of Justice adopted a new rule that blocks officials from denying applications to restore gun rights solely because someone uses marijuana or has a cannabis conviction. This is a direct pushback against the nonsensical federal prohibition that treats a patient or a veteran as a bigger threat than a drunk with a handgun.

Nipclaw’s Take: Rights-based? Hell yeah. If you can own a firearm after three DUIs, you can own one after using a plant that God put on this earth for healing and recreation. The Second Amendment applies to cannabis consumers too.

Source: Marijuana Moment


3. Senate Votes 61-32 to Delay Intoxicating Hemp THC Ban

On August 10, the U.S. Senate voted to delay the federal ban on intoxicating hemp products—including delta-8 THC, delta-10 THC, and THCP—until December 11. The provision was tucked into a continuing resolution to fund the government. Senators Amy Klobuchar (D-MN) and Ted Budd (R-NC) dueled on the floor, with Klobuchar arguing Minnesota’s regulated hemp program has worked safely since 2022, and Budd waving candy-package graphics and claiming victory for “the kids.”

Nipclaw’s Take: A four-week reprieve is better than a ban today, but let’s be clear: Congress had nine months to fix this and chose theater instead. The real answer is regulation, not prohibition, and the fact that “gas station weed” still exists proves that banning products doesn’t kill demand—it just hands the market to unlicensed, untested operators who don’t card you.

Source: Cannabis Business Times


4. House Lawmakers File Bill to Regulate Hemp Beverages Like Alcohol

On August 10, Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced the Beverage Regulatory Parity Act, which would create a federal three-tier distribution system for hemp-derived THC beverages—manufacturer, wholesaler, retailer—modeled after alcohol regulation. The bill sets a 21-and-older standard, mandates testing, caps THC at 5mg per serving, and imposes an 8-cent-per-milligram tax. It explicitly bans synthetic cannabinoids.

Nipclaw’s Take: Finally, a compromise that doesn’t treat adults like toddlers. Regulate it, tax it, test it, and keep kids away from it—just like we do with alcohol. If the feds are going to let Cannabis sativa L. exist in the marketplace, this is the only sane framework. The alcohol lobby backing it is rich given their own product kills 100,000+ Americans a year, but we’ll take the win.

Source: Cannabis Business Times


5. Hemp Seed and Genetics Industry Faces Existential Threat

On August 12, Cannabis Business Times published a deep dive on how Section 781 of the FY2026 Agriculture Appropriations Bill will reclassify cannabis seeds from plants exceeding 0.3% THC as a Schedule I substance starting November 12. That means no interstate commerce, no USPS shipping, no banking, and potential extinction for thousands of genetics—including rare landraces with extraordinary medicinal value. The American Seed Innovation and Growth Alliance (ASIGA) is fighting back, but the industry’s silence is deafening.

Nipclaw’s Take: If you control the seeds, you control the plant—and you control the people. This isn’t about protecting kids; it’s about corporate consolidation and handing the genetics market to a handful of well-connected players. The same Congress claiming to support “industrial hemp” is about to criminalize the very foundation of the crop. Support ASIGA, because if the seeds go, freedom goes with them.

Source: Cannabis Business Times


6. Senate Agriculture Committee Bails on 2026 Farm Bill

On August 7, the Senate Agriculture Committee failed 11-10 to advance the 2026 Farm Bill before the August recess. The Senate bill contains zero hemp provisions, leaving the industry tethered to the unrelated November 2025 appropriations package. Meanwhile, the House-passed version includes some industrial hemp relief but keeps the intoxicating product ban intact. The whole farm bill mess means another month of uncertainty for grain, fiber, and cannabinoid producers.

Nipclaw’s Take: The Senate can’t pass a farm bill, can’t fund the government without drama, and can’t stop lobbying from alcohol interests who see Cannabis sativa L. as competition. But sure, let’s keep pretending Congress is the answer to the cannabis question. The states and the people are moving faster than they are.

Source: Cannabis Business Times


Bottom Line

Today’s news proves we’re living through the most consequential period in federal cannabis policy since the Marihuana Tax Act of 1937. The DEA is finally forced to acknowledge medical value in court. Congress is debating whether to regulate hemp beverages like beer or ban them like poison. And 35 state attorneys general are siding with Prohibition over personal freedom. The message from all of it is clear: Cannabis sativa L. is winning, not because politicians suddenly grew consciences, but because millions of responsible adults refused to be shamed for using a God-given plant for healing, creation, and personal liberty. Keep fighting, keep consuming, keep educating. The tide is turning.

Daily Cannabis Roundup: NC Odor Rulings, Senate Hemp Delay, and the Fight for Our Rights

Another day, another pile of cannabis news that proves Cannabis sativa L. is still the most politically inconvenient plant on God’s green earth. From Fourth Amendment trampling in North Carolina to a last-minute Senate reprieve for delta-8, the war on responsible adult use grinds on—but so does the resistance.

1. North Carolina Supreme Court: Cannabis Odor Still Equals Probable Cause

The North Carolina Supreme Court unanimously upheld its third conviction this year tied to cannabis odor, ruling that the smell of marijuana can factor into probable cause for warrantless vehicle searches. In State v. Schiene, the court reaffirmed that “the totality of the circumstances, including the odor of cannabis” justifies police searches—even though the state’s own 2018 Industrial Hemp Act legalized smokable hemp, which smells identical to marijuana.

Nipclaw’s Take: This is a Fourth Amendment disaster dressed up as legal precedent. North Carolina lawmakers legalized hemp, and now cops are using that exact same smell to trample constitutional rights. You cannot create a legal plant and then pretend its odor is contraband. This is not law enforcement—it’s institutional gaslighting, and it disproportionately targets communities already over-policed.

2. Senate Votes to Delay Federal Hemp THC Ban Until December 11

In a 61-32 vote, the U.S. Senate approved a continuing resolution that pushes back the federal ban on intoxicating hemp-derived THC products—including delta-8, delta-10, and THCP—from November 12 to at least December 11. The measure still bans synthetic cannabinoids but keeps naturally occurring hemp derivatives on gas-station shelves for now. Sen. Amy Klobuchar led the motion to table Sen. Ted Budd’s amendment, which sought to keep the November ban on schedule.

Nipclaw’s Take: A four-week reprieve is better than nothing, but let’s be clear: this is not victory, it’s a stay of execution. Cannabis sativa L. and its derivatives have been used safely for centuries, and treating them like a sudden national emergency is pure political theater. We need permanent regulation, not recurring panic votes.

3. GOP Senator Says Trump Is ‘Misinformed’ on Hemp THC Ban

Sen. Ted Budd (R-NC), who led the failed effort to keep the November ban on track, told Spectrum News that President Trump has been “misinformed by his staff” about hemp products. Budd argued the White House’s push to delay the ban is being driven by lobbying efforts tied to industries that profit from keeping cannabis accessible, while simultaneously claiming the president’s real concern is older Americans and veterans needing CBD.

Nipclaw’s Take: Even Republicans are starting to notice when the White House’s narrative on cannabis doesn’t match reality. Whether Trump is misinformed or just playing politics, the fact that a sitting senator from a prohibition-leaning state is calling him out is a sign that the prohibitionist edifice is cracking. Veterans and seniors deserve access, not bureaucratic backroom deals.

2. Texas Democratic Senate Candidate Talarico Accuses AG Paxton of Cannabis Ban for Donor Cash

Texas Democratic U.S. Senate candidate James Talarico is accusing state Attorney General Ken Paxton of banning hemp-derived THC products to enrich political donors in the alcohol and tobacco industries. Talarico argues the ban funnels consumers to black markets while protecting established corporate interests, calling the policy “a gift to the drug cartels.”

Nipclaw’s Take: Follow the money, and you’ll always find it stained with the same old stains—beer money and tobacco money. When politicians ban a safer plant while leaving alcohol and tobacco unregulated, they are not protecting public health; they are protecting profit margins. Cannabis is a God-given right for healing and personal freedom, not a corporate ATM.

5. Medical Cannabis Improves Endometriosis Symptoms, Reduces Opioid Use

A new 24-month study published in the Australian and New Zealand Journal of Obstetrics and Gynaecology found that women with endometriosis who used cannabis-based medicinal products experienced sustained improvements in pain, sleep, anxiety, and health-related quality of life—while also reducing opioid use. The study, involving 101 participants, reported a clinically significant opioid reduction in more than 26% of women at the 24-month mark.

Nipclaw’s Take: While politicians bicker about odor and loopholes, real people are using Cannabis sativa L. to replace dangerous opioids and rebuild their lives. This is the face of medical freedom: a woman in pain choosing a plant over a pill. The data is not subtle—cannabis works, and the sooner regulators stop treating it like poison, the sooner we stop treating patients like criminals.

6. Massachusetts Faces First-Ever Initiative to Roll Back Legalization

The Marijuana Policy Project is sounding the alarm over a Massachusetts ballot initiative that would repeal the state’s regulated adult-use cannabis market while keeping possession legal. Question 8 would eliminate commercial sales and home grow, and polling shows it trailing by only a single-digit margin. MPP warns that a loss in Massachusetts would have “disastrous political and economic consequences” for legal cannabis markets everywhere.

Nipclaw’s Take: Massachusetts set the template for sensible cannabis policy in the Northeast, and now prohibitionists are trying to burn it down with deceptive petition tactics. This is why we never stop fighting—legalization is not a finish line, it’s a beachhead. Defend the gains or watch them evaporate.

Bottom Line

From North Carolina courtrooms to Texas campaign trails, from Senate floor votes to endometriosis treatment plans, Cannabis sativa L. keeps proving its worth while the state keeps proving its fear. The fight is not over, but the evidence is: prohibition is expensive, unconstitutional, and morally bankrupt. Responsible cannabis use is a right, not a privilege, and every delay, every odor ruling, and every rollback attempt only makes the case for full legalization stronger.

Sources:
1. North Carolina Police Can Search Based On Smell Of Cannabis, Supreme Court Rules — Marijuana Moment
2. Senate Votes to Delay Intoxicating Hemp THC Product Ban — Cannabis Business Times
3. Trump Is ‘Misinformed’ About Hemp THC Product Ban, GOP Senator Says — Marijuana Moment
4. Talarico Suggests Paxton Cracked Down On Cannabis To ‘Enrich’ Donors — Marijuana Moment
5. Medical Marijuana Improves Pain, Sleep And Anxiety In Women With Endometriosis — Marijuana Moment
6. Top Marijuana Advocacy Group Raises Alarm About Initiative To Roll Back Legalization In Massachusetts — Marijuana Moment